Project Grant R21EY037045
Award Date
2/1/25
Completion Date
1/31/27
Dollars Obligated
$234K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
The National Eye Institute (NEI), through its Vision Research federal grant program (CFDA 93.867), awarded a $679,159 Project Grant to The Schepens Eye Research Institute, Inc. in Boston, Massachusetts. The grant, awarded on May 1, 2025, supports research aimed at understanding how aging and elevated intraocular pressure (IOP) contribute to the development of glaucoma and impact retinal ganglion cells (RGCs). The research project will investigate the transcriptomic changes in RGCs due to aging...
This federal Project Grant award, totaling $496,633, was awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867). The grant supports a research project at Duke University to investigate the role of glypicans, specifically glypican-4 (GPC4), in trabecular meshwork function, intraocular pressure regulation, and the development of glaucoma. The project aims to uncover the molecular mechanisms by which augmented GPC4 expression and secretion may dysregulate Wnt...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $1,066,178 to Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC) to support late-stage preclinical development and GMP production of a novel extended-release intraocular pressure (IOP)-lowering formulation for the treatment of glaucoma. The funding will enable critical IND-enabling studies for this first-in-class drug candidate using the FDA-approved drug pregabalin as...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to develop universally immune-compatible induced pluripotent stem cells (iPSCs) for regenerative therapies to treat various eye conditions. The $492,500 award, granted on January 1, 2025, supports research at The Schepens Eye Research Institute, Inc. to generate iPSCs that express peptide-free or low-affinity peptide-loaded HLA-I molecules, protecting them from...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research to investigate the role of myeloid cells in axon damage and degeneration associated with glaucoma. The research aims to determine whether NAD+-boosting interventions, which have shown promise in promoting axon protection, work through an anti-inflammatory mechanism by inhibiting myeloid cell recruitment. The award provides $423,767.00 over a 2-year period...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of neural activity in improving retinal ganglion cell (RGC) replacement therapies for glaucoma. The $132,597 award to The Schepens Eye Research Institute, Inc. aims to: 1) characterize retinal remodeling following RGC inactivation, and 2) determine if inhibiting host neural activity can enhance the structural and functional integration...
This Project Grant award from the National Eye Institute (NEI), part of the U.S. Department of Health and Human Services (CFDA 93.867 - Vision Research), provides $661,635 to The Research Foundation for the State University of New York (RFSUNY) to elucidate the molecular changes in the extracellular matrix of the outflow pathway that regulate intraocular pressure in steroid-induced ocular hypertension and open-angle glaucoma. The key objectives are to determine if the extracellular matrix...
This federal Project Grant award of $387,428.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research to investigate mechanisms that drive optic nerve sensitivity to elevated intraocular pressure, a major risk factor for optic nerve damage in glaucoma. The overarching goal is to determine how transient biomechanical strains on the optic nerve head prime astrocytes to develop greater glaucomatous dysfunction via the mechanosensitive channel Piezo1. The award will...
The National Eye Institute (NEI) awarded a $417,162 Project Grant under the Vision Research program (CFDA 93.867) to the University of Houston System to develop and apply a polarization-sensitive swept source optical coherence tomography (PS-SSOCT) system for 3D mapping of the birefringent properties of the posterior eye in a non-human primate model. The goal is to quantify changes in birefringence within the retina, optic nerve head, and lamina cribrosa in response to changes in intraocular...